Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese
Abstract
The aim of this study was to investigate the allelic association of a single nucleotide polymorphism in exon 1 of the cytotoxic T-lymphocyte antigen-4 (CTLA4) gene with rheumatoid arthritis (RA) in Chinese people. One hundred and eighty-six unrelated adults with RA and 203 randomly selected normal adults were studied. All were ethnic Chinese living in Taiwan. The CTLA4 A-G polymorphism was genotyped with a polymerase chain reaction (PCR) and digestion with the restriction enzyme BstEII. The genotype and allele frequencies of CTLA4 in patients with rheumatoid arthritis differed significantly from those of adult controls (P=0.022 and P=0.037, respectively). Genotype CTLA4 49 G/G and allele G were associated with an increased risk of RA (RR=1.72, 95% CI=1.15-2.57, P=0.008; RR=1.39, 95% CI=1.02-1.89, P=0.037, respectively), whereas genotype A/G and allele A were associated with protection against RA (RR=0.58, 95% CI=0.39-0.87, P=0.008 and RR=0.72, 95% CI=0.53-0.98, P=0.037, respectively). We concluded that, the CTLA4 49 A-G polymorphism is associated with RA in Chinese patients from Taiwan.
Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady
Key Biomarkers
Symptom Clusters
Cited By (2)
Related Papers
- Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177Frontiers in Immunology · 2022 · 2 shared tags
- A Transcriptomic Fingerprint for Parkinson's Disease Found in Patients with Chronic Inflammatory Response Syndrome: Implications for Diagnosis, Treatment and PreventionMedical Research Archives · 2024 · 2 shared tags
- Inflammation and osteosarcopeniaOsteosarcopenia · 2022 · 2 shared tags
- A Narrative Review of the Immunomodulatory Effects of Acthar® Gel Beyond Its Steroidogenic PropertiesAdvances in Therapy · 2025 · 2 shared tags
- Phytoplankton Toxins and Their Potential Therapeutic Applications: A Journey toward the Quest for Potent PharmaceuticalsMarine Drugs · 2022 · 2 shared tags
- Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administrationImmunotherapy Advances · 2023 · 2 shared tags